Ipilimumab vs Ranitidine
Ipilimumab vs Ranitidine: Overview
This comparison examines the pharmacological differences between Ipilimumab and Ranitidine.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Ranitidine: Competitive H2 receptor antagonist.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Ranitidine — 2-3 hours.
Chemical Properties
Molecular Formula: Ranitidine — C13H22N4O3S.
Molecular Weight: Ranitidine — 314.4050 g/mol.
Type: Ipilimumab — Antibody; Ranitidine — Small molecule.